Reciprocating Holder Apparatus 7 - DATA SHEET

Significance of the topic

The ability to reliably test drug dissolution profiles under controlled conditions is essential in pharmaceutical development and quality control. Reciprocating holder systems offer a versatile approach to evaluate modified, extended and sustained release formulations by simulating in vivo dynamic conditions and providing consistent, reproducible results.

Objectives and overview

This summary reviews the Agilent Reciprocating Holder Apparatus 7 data sheet, highlighting its design goals, performance features and compliance with regulatory standards. The device is intended to streamline dissolution assays for a range of dosage forms, reducing manual intervention and improving throughput.

Methodology and instrumentation

The Apparatus 7 employs a programmable reciprocating motion that dips dosage forms through a 2 cm stroke into fresh dissolution media at defined time intervals. Key configuration options include:

• Tube volumes: standard 50 mL or optional 100 mL and 300 mL vessels.
• Holder types: reciprocating disk, angled disk, cylinder, acrylic rod and spring holders.
• Sample capacity: up to six samples per run in standard mode or two sets of six in the optional 12×12 station.
• Temperature control: water bath maintained at ambient+5 °C to 55 °C.
• Programmable parameters: dip rate (5–60 dips/min), run time, dip and drain intervals.

Main results and discussion

The Apparatus 7 is engineered for consistent batch-to-batch evaluation of drug release profiles. Its configurability allows selection of vessel size and holder type to match diverse dosage forms, including extended-release tablets and novel delivery systems. The reciprocating motion ensures uniform hydrodynamic conditions around the dosage form, enhancing comparability across tests. Compliance with USP Chapter <724> confirms its suitability for standardized dissolution testing.

Benefits and practical applications

This system delivers multiple advantages for pharmaceutical laboratories:

• Automation: sequential testing of up to 12 vessels without operator intervention.
• Versatility: interchangeable holders accommodate a wide range of formulations.
• Throughput: expanded stations support high-volume testing in R&D and QC.
• Regulatory alignment: built-in compliance streamlines method validation.

Future trends and potential applications

Advances in dissolution testing are moving toward greater integration with automated sampling, in situ spectroscopic monitoring and data analytics. The modular design of reciprocating systems like Apparatus 7 positions them well for adaptation to continuous manufacturing feedback loops, real-time release testing and complex controlled-release platforms.

Conclusion

The Agilent Reciprocating Holder Apparatus 7 offers a flexible, compliant and high-throughput solution for dissolution testing of modern dosage forms. Its programmable reciprocation, broad holder compatibility and temperature control capabilities make it a valuable tool in pharmaceutical development and quality assurance.